The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Siblings trying to make US water polo teams for Paris Olympics
Experts, execs stress responsible AI
All eyes on Xiaomi car to see if it can trump rivals
People shop for decorations for upcoming Halloween in Ontario, Canada
Kevin Pillar gets 1,000th career hit in Angels' win at Texas
China endeavors to build characteristic towns
Bamboo dance competition held at middle school in Hainan
Traditional dance helps reduce poverty in Shannan, Tibet
Georgia Republicans choose Amy Kremer, organizer of pro
Coal production in China reach historic highs last year
Children are evacuated from school 'during an exam' after threat made via email
Xi Extends Condolences to Nepali President over Strong Quake